TrialBreast cancer research and treatment2013

CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.

K Beelen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.